Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,287
Total Claims
$3.7M
Drug Cost
946
Beneficiaries
$3,955
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+1%
Cost per patient vs peers
$3,955 vs $3,933 avg
-30%
Brand preference vs peers
36.0% vs 51.2% avg
Brand vs Generic
Brand: 7,941 claims · $3.4M
Generic: 14,122 claims · $358K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 673 | $485K |
| Semaglutide | 324 | $310K |
| Dulaglutide | 278 | $285K |
| Insulin Lispro | 276 | $251K |
| Empagliflozin | 263 | $226K |
| Levothyroxine Sodium | 3,289 | $219K |
| Sitagliptin Phos/Metformin Hcl | 177 | $148K |
| Sitagliptin Phosphate | 153 | $128K |
| Dapaglifloz Propaned/Metformin | 143 | $98K |
| Sitagliptin Phos/Metformin Hcl | 102 | $81K |
| Insulin Glargine,hum.Rec.Anlog | 180 | $81K |
| Insulin Lispro Protamin/Lispro | 113 | $78K |
| Empagliflozin/Linagliptin | 101 | $72K |
| Empagliflozin/Metformin Hcl | 77 | $69K |
| Insulin Glargine,hum.Rec.Anlog | 136 | $68K |
Prescribing Profile
Patient Profile
74
Avg Age
74%
Female
1.83
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data